drugset / Trial / NCT04238637
Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
Phase 2
Active not recruiting
50 enrolled
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
AstraZeneca · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A multicenter Phase II, randomized, prospective, open-label Trial investigating the clinical impact on combining Specific Internal Radiotherapy (SIRT) with the PD1-L Inhibitor Durvalumab and the CTLA-4 Inhibitor Tremelimumab in patients with intrahepatic Biliary Tract Cancer
Timeline
- Start
- 2019-11-01
- Primary completion
- 2026-08
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | — | Intravenous |